| Assay ID | Title | Year | Journal | Article |
|---|
| AID305861 | Binding affinity to human cloned dopamine D4.4 receptor expressed in CHO cells | 2007 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
| Dopamine/serotonin receptor ligands. Part 15: Oxygenation of the benz-indolo-azecine LE 300 leads to novel subnanomolar dopamine D1/D5 antagonists. |
| AID452079 | Agonist activity at human dopamine D1 receptor expressed in HEK293 cells assessed as intracellular calcium by fluorescence microplate reader | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
| Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities? |
| AID261575 | Inhibition of D1 dopamine receptor in HEK 293 cells by intracellular calcium assay | 2006 | Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
| Dopamine/serotonin receptor ligands. 12(1): SAR studies on hexahydro-dibenz[d,g]azecines lead to 4-chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the first picomolar D5-selective dopamine-receptor antagonist. |
| AID261570 | Displacement of [3H]SCH 23390 from D1 dopamine receptor | 2006 | Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
| Dopamine/serotonin receptor ligands. 12(1): SAR studies on hexahydro-dibenz[d,g]azecines lead to 4-chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the first picomolar D5-selective dopamine-receptor antagonist. |
| AID452076 | Displacement of [3H]SCH23390 from human dopamine D5 receptor expressed in CHO cells by scintillation counting | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
| Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities? |
| AID305864 | Agonist activity at human dopamine D2 receptor assessed as increase in intramolecular calcium concentration by calcium fluorescence assay | 2007 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
| Dopamine/serotonin receptor ligands. Part 15: Oxygenation of the benz-indolo-azecine LE 300 leads to novel subnanomolar dopamine D1/D5 antagonists. |
| AID261576 | Inhibition of D2L dopamine receptor in HEK 293 cells by intracellular calcium assay | 2006 | Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
| Dopamine/serotonin receptor ligands. 12(1): SAR studies on hexahydro-dibenz[d,g]azecines lead to 4-chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the first picomolar D5-selective dopamine-receptor antagonist. |
| AID343051 | Displacement of [3H]SCH23390 from human cloned dopamine D2L receptor | 2008 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
| Dopamine/serotonin receptor ligands. Part 17: a cross-target SAR approach: affinities of azecine-styled ligands for 5-HT(2A) versus D1 and D2 receptors. |
| AID261572 | Binding affinity to D3 dopamine receptor by radioligand binding assay | 2006 | Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
| Dopamine/serotonin receptor ligands. 12(1): SAR studies on hexahydro-dibenz[d,g]azecines lead to 4-chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the first picomolar D5-selective dopamine-receptor antagonist. |
| AID261571 | Displacement of [3H]spiperone from D2L dopamine receptor | 2006 | Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
| Dopamine/serotonin receptor ligands. 12(1): SAR studies on hexahydro-dibenz[d,g]azecines lead to 4-chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the first picomolar D5-selective dopamine-receptor antagonist. |
| AID305859 | Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in CHO cells | 2007 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
| Dopamine/serotonin receptor ligands. Part 15: Oxygenation of the benz-indolo-azecine LE 300 leads to novel subnanomolar dopamine D1/D5 antagonists. |
| AID305865 | Agonist activity at human dopamine D5 receptor assessed as increase in intramolecular calcium concentration by calcium fluorescence assay | 2007 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
| Dopamine/serotonin receptor ligands. Part 15: Oxygenation of the benz-indolo-azecine LE 300 leads to novel subnanomolar dopamine D1/D5 antagonists. |
| AID343052 | Antagonist activity at serotonin 5HT2A receptor assessed as effect on 5HT-induced isometric contractile force in isolated rings of pig coronary artery | 2008 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
| Dopamine/serotonin receptor ligands. Part 17: a cross-target SAR approach: affinities of azecine-styled ligands for 5-HT(2A) versus D1 and D2 receptors. |
| AID261578 | Inhibition of D5 dopamine receptor in HEK 293 cells by intracellular calcium assay | 2006 | Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
| Dopamine/serotonin receptor ligands. 12(1): SAR studies on hexahydro-dibenz[d,g]azecines lead to 4-chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the first picomolar D5-selective dopamine-receptor antagonist. |
| AID452074 | Displacement of [3H]spiperone from human dopamine D3 receptor expressed in CHO cells by scintillation counting | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
| Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities? |
| AID452075 | Displacement of [3H]spiperone from human dopamine D4 receptor expressed in CHO cells by scintillation counting | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
| Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities? |
| AID305863 | Agonist activity at human dopamine D1 receptor assessed as increase in intramolecular calcium concentration by calcium fluorescence assay | 2007 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
| Dopamine/serotonin receptor ligands. Part 15: Oxygenation of the benz-indolo-azecine LE 300 leads to novel subnanomolar dopamine D1/D5 antagonists. |
| AID452072 | Displacement of [3H]SCH23390 from human dopamine D1 receptor expressed in CHO cells by scintillation counting | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
| Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities? |
| AID452077 | Antagonist activity at human dopamine D1 receptor expressed in HEK293 cells assessed as SKF-38393-induced intracellular calcium by fluorescence microplate reader | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
| Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities? |
| AID261577 | Inhibition of D3 dopamine receptor in HEK 293 cells by intracellular calcium assay | 2006 | Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
| Dopamine/serotonin receptor ligands. 12(1): SAR studies on hexahydro-dibenz[d,g]azecines lead to 4-chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the first picomolar D5-selective dopamine-receptor antagonist. |
| AID305862 | Binding affinity to human cloned dopamine D5 receptor expressed in HEK 293 cells | 2007 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
| Dopamine/serotonin receptor ligands. Part 15: Oxygenation of the benz-indolo-azecine LE 300 leads to novel subnanomolar dopamine D1/D5 antagonists. |
| AID305860 | Binding affinity to human cloned dopamine D3 receptor expressed in CHO cells | 2007 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
| Dopamine/serotonin receptor ligands. Part 15: Oxygenation of the benz-indolo-azecine LE 300 leads to novel subnanomolar dopamine D1/D5 antagonists. |
| AID297409 | Displacement of [3H]SCH 23390 from human dopamine D5 receptor expressed in HEK293 cells | 2007 | Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
| Dopamine/serotonin receptor ligands. 16.(1) Expanding dibenz[d,g]azecines to 11- and 12-membered homologues. Interaction with dopamine D(1)-D(5) receptors. |
| AID343050 | Displacement of [3H]SCH23390 from human cloned dopamine D1 receptor | 2008 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
| Dopamine/serotonin receptor ligands. Part 17: a cross-target SAR approach: affinities of azecine-styled ligands for 5-HT(2A) versus D1 and D2 receptors. |
| AID452080 | Agonist activity at human dopamine D2L receptor expressed in HEK293 cells assessed as intracellular calcium by fluorescence microplate reader | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
| Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities? |
| AID305858 | Displacement of [3H]SCH 23390 from human cloned dopamine D1 receptor expressed in HEK 293 cells | 2007 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
| Dopamine/serotonin receptor ligands. Part 15: Oxygenation of the benz-indolo-azecine LE 300 leads to novel subnanomolar dopamine D1/D5 antagonists. |
| AID261573 | Binding affinity to D5 dopamine receptor by radioligand binding assay | 2006 | Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
| Dopamine/serotonin receptor ligands. 12(1): SAR studies on hexahydro-dibenz[d,g]azecines lead to 4-chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the first picomolar D5-selective dopamine-receptor antagonist. |
| AID452078 | Antagonist activity at human dopamine D2L receptor expressed in HEK293 cells assessed as quinpirole-induced intracellular calcium by fluorescence microplate reader | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
| Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities? |
| AID452073 | Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells by scintillation counting | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
| Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities? |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |